12.77

3.04% -0.40

Trevi Therapeutics Inc (TRVI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$13.17

Aprire:

$13.12

Volume 24 ore:

1.84M

Relative Volume:

0.90

Capitalizzazione di mercato:

$1.64B

Reddito:

Utile/perdita netta:

$-29.07M

Rapporto P/E:

-44.03

EPS:

-0.29

Flusso di cassa netto:

$-31.85M

1 W Prestazione:

-5.20%

1M Prestazione:

+7.76%

6M Prestazione:

+106.97%

1 anno Prestazione:

+254.72%

Intervallo 1D:

$12.71

$13.45

Intervallo di 1 settimana:

$12.71

$14.39

Portata 52W:

$3.4715

$14.39

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Nome

Trevi Therapeutics Inc

Settore

Healthcare (1123)

Industria

Biotechnology (627)

Telefono

203-304-2499

Indirizzo

195 CHURCH STREET, NEW HAVEN, CT

Dipendente

Cinguettio

@TreviThera

Prossima data di guadagno

2025-03-18

Ultimi documenti SEC

TRVI's Discussions on Twitter

Confronta TRVI con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TRVI Trevi Therapeutics Inc	12.77	1.69B	0	-29.07M	-31.85M	-0.29
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-11-13	Iniziato	Leerink Partners	Outperform
2025-08-21	Iniziato	Morgan Stanley	Overweight
2025-07-01	Iniziato	Cantor Fitzgerald	Overweight
2025-05-28	Iniziato	H.C. Wainwright	Buy
2025-03-10	Reiterato	Needham	Buy
2025-03-10	Aggiornamento	Raymond James	Outperform → Strong Buy
2024-12-12	Reiterato	H.C. Wainwright	Buy
2024-09-09	Ripresa	Leerink Partners	Outperform
2024-08-30	Iniziato	H.C. Wainwright	Buy
2024-08-30	Iniziato	Raymond James	Outperform
2024-06-13	Iniziato	Rodman & Renshaw	Buy
2023-04-12	Iniziato	B. Riley Securities	Buy
2022-11-22	Iniziato	SVB Leerink	Outperform
2019-06-03	Iniziato	BMO Capital Markets	Outperform
2019-06-03	Iniziato	Needham	Buy
2019-06-03	Iniziato	SVB Leerink	Outperform
2019-06-03	Iniziato	Stifel	Buy

Mostra tutto

Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie

Dec 11, 2025

Trevi Therapeutics stock hits all-time high of 14.01 USD By Investing.com - Investing.com Nigeria

Dec 11, 2025

Marshall Wace LLP Has $13.55 Million Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat

Dec 11, 2025

Trevi Therapeutics Stock Surges to Record High on Clinical and Strategic Momentum - AD HOC NEWS

Dec 11, 2025

Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighTime to Buy? - MarketBeat

Dec 11, 2025

Dec 10, 2025

226,381 Shares in Trevi Therapeutics, Inc. $TRVI Bought by Prudential Financial Inc. - MarketBeat

Dec 07, 2025

Dec 06, 2025

Trevi Therapeutics Appoints New Chief Financial Officer - The Globe and Mail

Dec 06, 2025

Affinity Asset Advisors LLC Raises Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat

Dec 06, 2025

Dec 05, 2025

Trevi Therapeutics appoints David Hastings as chief financial officer By Investing.com - Investing.com Nigeria

Dec 05, 2025

Trevi Therapeutics, Inc. Announces Appointment of David Hastings as Chief Financial Officer, Effective January 6, 2026 - marketscreener.com

Dec 05, 2025

Trevi Therapeutics, Inc. Announces the Hiring of David Hastings to Serve as the Company?s Principal Financial Officer, Effective January 6, 2026 - marketscreener.com

Dec 05, 2025

New Haven biotech names new CFO - Hartford Business Journal

Dec 05, 2025

Trevi Therapeutics appoints David Hastings as chief financial officer - Investing.com

Dec 05, 2025